SOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it was selected for an oral presentation at the 33rd International Cannabinoid…Read More
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART1211 at the 33rd Annual International Cannabinoid Research Society Symposium Artelo Biosciences NASDAQARTL
